|
AU713045B2
(en)
*
|
1995-05-01 |
1999-11-25 |
Scarista Limited |
Nicotinic acid esters and pharmaceutical compositions containing them
|
|
USRE40546E1
(en)
*
|
1996-05-01 |
2008-10-21 |
Scarista, Ltd. |
1,3-Propane diol esters and ethers and methods for their use in drug delivery
|
|
MY118354A
(en)
*
|
1995-05-01 |
2004-10-30 |
Scarista Ltd |
1,3-propane diol derivatives as bioactive compounds
|
|
US5795909A
(en)
*
|
1996-05-22 |
1998-08-18 |
Neuromedica, Inc. |
DHA-pharmaceutical agent conjugates of taxanes
|
|
US6576636B2
(en)
*
|
1996-05-22 |
2003-06-10 |
Protarga, Inc. |
Method of treating a liver disorder with fatty acid-antiviral agent conjugates
|
|
US6255347B1
(en)
|
1996-06-21 |
2001-07-03 |
Advanced Research And Technology Institute |
Methods and compositions comprising R-ibuprofen
|
|
US5869524A
(en)
*
|
1996-11-12 |
1999-02-09 |
American Home Products Corporation |
Indene inhibitors of COX-2
|
|
KR20000053227A
(ko)
*
|
1996-11-12 |
2000-08-25 |
이곤 이 버그 |
Cox-2의 인덴 억제제
|
|
AU5727798A
(en)
*
|
1996-12-23 |
1998-07-17 |
Texas A & M University, The |
Anti-amyloidogenic agents
|
|
AU6959898A
(en)
|
1997-04-11 |
1998-11-11 |
David J. Grainger |
Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
|
|
ES2302373T3
(es)
*
|
1998-02-13 |
2008-07-01 |
Nutramax Laboratories, Inc. |
Agentes y metodos para la proteccion, tratamiento y reparacion de tejidos conectivos.
|
|
US7141266B2
(en)
*
|
1998-05-21 |
2006-11-28 |
Beech-Nut Nutrition Corporation |
Baby-food compositions enhancing visual acuity and methods therefor
|
|
US6579551B1
(en)
|
1998-05-21 |
2003-06-17 |
Beech-Nut Nutrition Corporation |
Baby-food compositions containing egg yolk and methods therefor
|
|
US7413759B2
(en)
*
|
1998-05-21 |
2008-08-19 |
Beech-Nut Nutrition Corporation |
Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
|
|
US6149964A
(en)
*
|
1998-05-21 |
2000-11-21 |
Beech-Nut Nutrition Corporation |
Egg yolk-containing baby food compositions and methods therefor
|
|
US6572871B1
(en)
*
|
1999-01-06 |
2003-06-03 |
W. Edward Church |
Pain treatment method and apparatus using heating wrap and analgesic cream
|
|
US20040073258A1
(en)
*
|
1999-01-06 |
2004-04-15 |
Church W. Edward |
Body tissue and skin treatment method using pulsing heating pad and topical cream
|
|
GB9901809D0
(en)
*
|
1999-01-27 |
1999-03-17 |
Scarista Limited |
Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
|
|
US7235583B1
(en)
*
|
1999-03-09 |
2007-06-26 |
Luitpold Pharmaceuticals, Inc., |
Fatty acid-anticancer conjugates and uses thereof
|
|
US6426367B1
(en)
*
|
1999-09-09 |
2002-07-30 |
Efa Sciences Llc |
Methods for selectively occluding blood supplies to neoplasias
|
|
WO2001078721A1
(en)
*
|
2000-04-13 |
2001-10-25 |
Mayo Foundation For Medical Education And Research |
Aβ42 LOWERING AGENTS
|
|
US20060004086A1
(en)
*
|
2000-04-13 |
2006-01-05 |
Mayo Foundation For Medical Education And Research |
Method of reducing Abeta42 and treating diseases
|
|
AU2001275036A1
(en)
*
|
2000-06-02 |
2001-12-17 |
Medinox, Inc. |
Protected forms of a combination of pharmacologically active agents and uses therefor
|
|
US6306842B1
(en)
*
|
2000-06-02 |
2001-10-23 |
Medinox, Inc. |
Protected forms of a combination of pharmacologically active agents and uses therefor
|
|
US6927239B1
(en)
|
2000-08-02 |
2005-08-09 |
Pharmanutrients |
Methods and compositions for the attenuation and/or prevention of stress/catabolic responses
|
|
US6838451B1
(en)
|
2000-08-02 |
2005-01-04 |
Pharmanutrients |
Methods and compositions for the prevention and treatment of inflammation, osteoarthritis, and other degenerative joint diseases
|
|
WO2002009725A1
(en)
*
|
2000-08-02 |
2002-02-07 |
Pharmanutrients |
Methods and compositions for the prevention and treatment of inflamation, osteoarthritis, and other degenerative joint diseases
|
|
EP1305017A4
(en)
|
2000-08-02 |
2004-01-14 |
Pharmanutrients |
METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF SYNDROME X
|
|
EP1349554A2
(en)
*
|
2000-12-14 |
2003-10-08 |
Tufts University |
Compositions and methods for treating an arthritic condition
|
|
JP2005500988A
(ja)
*
|
2001-03-23 |
2005-01-13 |
ルイトポルド・ファーマシューティカルズ・インコーポレーテッド |
脂肪族アミン薬物複合体
|
|
US7816398B2
(en)
*
|
2001-03-23 |
2010-10-19 |
Luitpold Pharmaceuticals, Inc. |
Fatty alcohol drug conjugates
|
|
GB0111282D0
(en)
*
|
2001-05-09 |
2001-06-27 |
Laxdale Ltd |
Potentiation of therapeutic effects of fatty acids
|
|
JP3977162B2
(ja)
*
|
2002-06-21 |
2007-09-19 |
株式会社バンダイナムコゲームス |
キャラクタ情報管理装置、プログラム及び情報記憶媒体
|
|
EP1603548A4
(en)
*
|
2003-02-05 |
2007-10-10 |
Myriad Genetics Inc |
METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
|
|
WO2005065069A2
(en)
*
|
2003-07-11 |
2005-07-21 |
Myriad Genetics, Inc. |
Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
|
|
US20050154059A1
(en)
*
|
2004-01-13 |
2005-07-14 |
Cook Mark E. |
Method of treating type III hypersensitive reaction-related diseases and conditions by using conjugated linoleic acid
|
|
US20090155903A1
(en)
*
|
2004-03-19 |
2009-06-18 |
Myriad Genetics, Incorporated |
Pharmaceutical composition and method
|
|
WO2006001877A2
(en)
*
|
2004-04-13 |
2006-01-05 |
Myriad Genetics, Inc. |
Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
|
|
KR20070004036A
(ko)
*
|
2004-04-29 |
2007-01-05 |
키스톤 리테이닝 월 시스템스, 아이엔씨 |
벽, 옹벽 및 그 외 유사한 것을 위한 베니어
|
|
BRPI0514303A
(pt)
*
|
2004-08-11 |
2008-06-10 |
Myriad Genetics Inc |
composição farmacêutica e método para tratar distúrbios neurodegenerativos
|
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
US7893106B2
(en)
*
|
2004-11-19 |
2011-02-22 |
Martek Biosciences, Corporation |
Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
|
|
NZ555394A
(en)
*
|
2004-11-19 |
2010-07-30 |
Martek Biosciences Corp |
Oxylipins from long chain polyunsaturated fatty acids including docosapentaenoic acid and docosatetraenoic acid (DPA and DTA) and methods of making and using the same
|
|
US20090318394A1
(en)
*
|
2004-11-19 |
2009-12-24 |
Julie Nauroth |
Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
|
|
BRPI0613611A2
(pt)
*
|
2005-07-22 |
2011-01-18 |
Myriad Genetics Inc |
formulações de alta concentração de fármaco e formas de dosagens
|
|
EP1983977A4
(en)
*
|
2006-01-31 |
2011-11-30 |
Martek Biosciences Corp |
OXYLIPINES FROM STEARIDONIC ACID AND GAMMA-LINOLIC ACID AND METHOD FOR THE PRODUCTION AND USE THEREOF
|
|
EP2046119A2
(en)
*
|
2006-07-07 |
2009-04-15 |
Myriad Genetics, Inc. |
Treatment of psychiatric disorders
|
|
US20110190389A1
(en)
*
|
2007-02-20 |
2011-08-04 |
Linda Arterburn |
Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
|
|
WO2008153722A1
(en)
*
|
2007-05-22 |
2008-12-18 |
The Board Of Regents Of The University Of Texas System |
Post-translational regulation of catalytic activities of cytochrome p450 46a1 and uses thereof
|
|
WO2009086281A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Martek Biosciences Corporation |
Method for preparation of oxylipins
|
|
DK2315740T3
(en)
*
|
2008-07-08 |
2018-01-08 |
Catabasis Pharmaceuticals Inc |
Fatty Acid Acetylated Salicylates and Their Uses
|
|
US9085527B2
(en)
|
2008-07-08 |
2015-07-21 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid acylated salicylates and their uses
|
|
PL2334295T3
(pl)
|
2008-09-02 |
2017-12-29 |
Amarin Pharmaceuticals Ltd |
Kompozycja farmaceutyczna zawierająca kwas eikozapentaenowy i kwas nikotynowy oraz sposoby jej zastosowania
|
|
US20110229565A1
(en)
*
|
2008-09-17 |
2011-09-22 |
Karp Jeffrey M |
Drug Delivery Composition Comprising a Self-Assembled Gelator
|
|
AR073997A1
(es)
|
2008-10-29 |
2010-12-15 |
Wyeth Corp |
Formulaciones de moleculas de union a antigeno de dominio unico. metodo. kit
|
|
AU2009314311B2
(en)
|
2008-10-29 |
2013-01-10 |
Ablynx N.V. |
Methods for purification of single domain antigen binding molecules
|
|
SI2596786T1
(sl)
|
2009-02-10 |
2020-03-31 |
Amarin Pharmaceuticals Ireland Limited, |
Uporaba etilestra eikozapentaenojske kisline za zdravljenje hipertrigliceridemije
|
|
CN104856985B
(zh)
|
2009-04-29 |
2019-01-04 |
阿马里纳制药爱尔兰有限公司 |
稳定的药物组合物和使用其的方法
|
|
NZ720946A
(en)
|
2009-04-29 |
2017-09-29 |
Amarin Pharmaceuticals Ie Ltd |
Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
|
|
CA3026006C
(en)
|
2009-06-15 |
2021-09-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
|
|
US8304551B2
(en)
|
2009-09-01 |
2012-11-06 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid niacin conjugates and their uses
|
|
USRE46608E1
(en)
|
2009-09-01 |
2017-11-14 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid niacin conjugates and their uses
|
|
US20110064813A1
(en)
*
|
2009-09-16 |
2011-03-17 |
Charles Vaughn |
Use of salsalate with or without caffeine and with or without omega 3, and other pharmaceutical compounds in a distinctively unique nano-particulate capsule and tablet
|
|
WO2011038122A1
(en)
|
2009-09-23 |
2011-03-31 |
Amarin Corporation Plc |
Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
|
|
CN102781236B
(zh)
|
2009-12-31 |
2015-01-07 |
凯姆制药公司 |
喹硫平的氨基酸缀合物、其制备和使用方法
|
|
CN102822141A
(zh)
*
|
2010-01-20 |
2012-12-12 |
普罗诺瓦生物医药挪威公司 |
水杨酸脂肪酸衍生物
|
|
MX337315B
(es)
*
|
2010-03-04 |
2016-02-25 |
Amarin Pharma Inc |
Composiciones y metodos para tratar y/o prevenir enfermedad cardiovascular.
|
|
WO2011109681A1
(en)
*
|
2010-03-05 |
2011-09-09 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid cox inhibitor derivatives and their uses
|
|
EP2544536B1
(en)
|
2010-03-11 |
2018-12-12 |
Kempharm, Inc. |
Fatty acid conjugates of quetiapine, process for making and using the same
|
|
US20130045939A1
(en)
*
|
2010-03-19 |
2013-02-21 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid macrolide derivatives and their uses
|
|
CN103119062A
(zh)
*
|
2010-07-16 |
2013-05-22 |
埃博灵克斯股份有限公司 |
修饰的单结构域抗原结合分子及其应用
|
|
JP2013540757A
(ja)
|
2010-09-24 |
2013-11-07 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
カプセル化された作用物質の放出を制御する能力を有するナノ構造ゲル
|
|
US20140127289A1
(en)
|
2010-11-29 |
2014-05-08 |
Armarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
|
WO2012087745A1
(en)
*
|
2010-12-21 |
2012-06-28 |
Nestec S.A. |
Methods and compositions for preventing and treating osteoarthritis
|
|
US9730884B2
(en)
|
2011-09-29 |
2017-08-15 |
Plx Opco Inc. |
pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
|
|
US20130131170A1
(en)
|
2011-11-07 |
2013-05-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
|
JP6307442B2
(ja)
|
2012-01-06 |
2018-04-04 |
アマリン ファーマシューティカルス アイルランド リミテッド |
対象の高感度(hs−crp)のレベルを低下させる組成物および方法
|
|
RS67161B1
(sr)
|
2012-06-29 |
2025-09-30 |
Amarin Pharmaceuticals Ie Ltd |
Etil estar eikozapentaenske kiseline za upotrebu u smanjenju rizika od nesmrtonosnog šloga kod pacijenta na terapiji statinima
|
|
WO2014074552A2
(en)
|
2012-11-06 |
2014-05-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
|
|
US9814733B2
(en)
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
|
AU2014369916A1
(en)
|
2013-12-24 |
2016-06-16 |
Durect Corporation |
Uses of oxygenated cholesterol sulfates (OCS)
|
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
|
WO2015195662A1
(en)
|
2014-06-16 |
2015-12-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
|
|
US9603869B2
(en)
|
2015-05-22 |
2017-03-28 |
University Of South Florida |
Lithium co-crystals and an additional neuropsychiatric agent for treatment of neuropsychiatric disorders
|
|
CN108289833B
(zh)
|
2015-10-08 |
2022-01-25 |
布里格姆及妇女医院股份有限公司 |
用于递送囊封剂的稳定的已组装纳米结构
|
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
|
US10568840B2
(en)
|
2016-05-06 |
2020-02-25 |
The Brigham And Women's Hospital, Inc. |
Self assembled gels for controlled delivery of encapsulated agents to cartilage
|
|
US11020410B2
(en)
|
2017-02-03 |
2021-06-01 |
The Brigham And Women's Hospital, Inc. |
Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof
|
|
AU2018266131B2
(en)
|
2017-05-08 |
2021-07-29 |
Alivio Therapeutics, Inc. |
Formulation of nanostructured gels for increased agent loading and adhesion
|
|
WO2018213663A1
(en)
|
2017-05-19 |
2018-11-22 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject having reduced kidney function
|
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
|
MA50490A
(fr)
|
2018-09-24 |
2020-09-02 |
Amarin Pharmaceuticals Ie Ltd |
Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
|
|
BR112022009189A2
(pt)
|
2019-11-12 |
2022-07-26 |
Amarin Pharmaceuticals Ie Ltd |
Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
|
|
CN115666523A
(zh)
|
2020-03-26 |
2023-01-31 |
Plx 奥普科有限公司 |
能够进行pH依赖性重构的药物载体及其制备和使用方法
|
|
AU2022263358A1
(en)
|
2021-04-21 |
2023-11-30 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of heart failure
|